Panel okays drug to lower breast ca risk.
The Oncologic Drugs Advisory Committee on July 24 recommended approval of raloxifene, a selective estrogen receptor modulator. Raloxifene was originally approved by the FDA in 1997 to prevent and treat osteoporosis in postmenopausal women. According to a statement from Eli Lilly and Co., which markets raloxifene as Evista, more than 52 million prescriptions for the drug have been filled since its approval.
Using data from 37,000 postmenopausal women over a 10-year period, Eli Lilly submitted a new drug application to the FDA in 2006 to extend the drug's use to reducing breast cancer risk in this same group of patients.
If approved, Evista would be the "first and only therapy available to address two leading health issues for postmenopausal women--osteoporosis and breast cancer," Gwen Krivi, Ph.D., vice president of Lilly Research Laboratories, said in a written statement.
Although the committee voted to approve the indication for breast cancer risk reduction in postmenopausal women with osteoporosis (8-6) and in postmenopausal women at high risk for breast cancer (10-4), the FDA is not obligated to approve these new indications.
To help the advisory committee make its decision, the committee reviewed four large studies also submitted in the application, including the Study of Tamoxifen and Raloxifene (STAR) trial, Raloxifene Use for the Heart (RUTH) trial, Multiple Outcomes of Raloxifene Evaluation (MORE), and the Continuing Outcomes Relevant to Evista (CORE) trials.
Dr. Wulf Utian, executive director of the North American Menopause Society, said in an interview that the advisory committee's decision was a positive step that "increases the [number] of products available as potential reducers of breast cancer."
Currently, tamoxifen is the only other drug indicated for the reduction of breast cancer incidence in women at high risk for the disease.
Dr. Utian said that the committee's recommendation to approve raloxifene for the two new indications comes at a good time, as tamoxifen sales and use have been "disappointing" due to various side effects and particularly the increased risk of uterine cancer associated with the drug. Dr. Utian said that he serves as a consultant to various pharmaceutical companies, including Eli Lilly and some of its competitors.
According to Dr. Utian, both doctors and patients may be more accepting of raloxifene because it is already a well-known product for osteoporosis in postmenopausal patients, and its added benefit of reducing breast cancer would make it a viable alternative to tamoxifen for these women.
When published last year, the RUTH study raised some concerns about risk of death from stroke and the incidence of blood clots associated with raloxifene use (N. Engl. J. Med. 2006;355:125-37).
Various experts questioned this stroke risk, including Marcia Stefanick, Ph.D., from Stanford (Calif.) University, who wrote an accompanying editorial about the study. "What level of breast cancer risk would justify the use of raloxifene for the prevention of breast cancer for a given person, if one takes into account the competing risks and patient preferences? Complicating the answer is our inability to predict these risks with high accuracy on an individual basis," she wrote (N. Engl. J. Med. 2006;355:190-2).
Dr. Utian said that the prevalence of both stroke and venous thromboembolism increases with age. He emphasized, however, that most women who would start taking tamoxifen or raloxifene for prevention would do so at a younger age, when both the prevalence and absolute risk for these adverse events would be lower.
"The absolute risk is really not high. I think the balance would be in favor of the use of this drug," he said.
BY LORINDA BULLOCK
|Printer friendly Cite/link Email Feedback|
|Publication:||Internal Medicine News|
|Date:||Aug 15, 2007|
|Previous Article:||FDA panel favors keeping c on market.|
|Next Article:||False-positive findings rife in some types of cancer screening.|